Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG (BAYN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Covestro : names new CEO to replace Patrick Thomas

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/26/2017 | 02:39pm CEST

Patrick Thomas is to retire as CEO of Covestro to be replaced by its current chief commercial officer Marcus Steileman, the company announced 24 May.

The transition will take place in the third quarter of 2018. Thomas will remain chairman of the board of management of the Leverkusen-based suppliers of polyurethane, polycarbonate and other polymer technologies.

With the end of his contract in fall 2018, Patrick Thomas will have been at the top of Covestro for more than ten years and of course we respect this step. Under his leadership, the company has achieved remarkable success, said Richard Pott, chairman of Covestros supervisory board.

Thomas has led Covestro which was spun-out from Bayer AG in 2015, having comprised the main part of the groups Bayer MaterialScience division for 13 years prior.

I would like to take this opportunity to thank all employees at Covestro, said its long-standing CEO. They have done a great job in the last few years and made Covestro a very successful company. I look forward to ensuring a successful transition over the next 16 months.

Regarding Thomas replacement. Pott said: We have examined potential candidates for succession in advance and come to the conclusion that we have an excellent successor in our own ranks with Markus Steileman.

(c) 2017 News Central Asia (nCa). All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER AG
05/26 COVESTRO : names new CEO to replace Patrick Thomas
05/25 BAYER : Findings from Bayer Has Provided New Data on Non-Small Cell Lung Cancer ..
05/24 BAYER : Federal Contracts Awarded by Federal Agencies in Connecticut (May 24)
05/24 DGAP-ADHOC : Covestro AG: CEO succession planning
05/24 Freeze Drying Agenda Released for Lyophilization USA 2017
05/23 GLOBAL HERBICIDE RESISTANCE CHALLENG : Adrian Percy: ”We invest in finding..
05/23 BAYER : $165,000 Federal Contract Awarded to iMed Biomedical
05/20 COVESTRO : to expand CO2-using processes
05/19 BAYER : Combine Solicitation - MEDRAD Injector Maintenance
05/18 RESEARCHERS AT BAYER TARGET HEART DI : A Prodrug of a Partial Adenosine A Recept..
More news
Sector news : Pharmaceuticals - NEC
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/23 Mergers And Acquisitions - Capturing The Gain (Of Acquirees)
05/21 Tracking Dan Loeb's Third Point Portfolio - Q1 2017 Update
05/18 3 THINGS IN BIOTECH YOU SHOULD LEARN : May 18, 2017
05/18 Bayer on deck with nine abstracts at ASCO
05/17 FDA grants Priority Review for Bayer's NDA for copanlisib for follicular lymp..
Advertisement
Financials (€)
Sales 2017 50 026 M
EBIT 2017 9 706 M
Net income 2017 5 752 M
Debt 2017 10 907 M
Yield 2017 2,45%
P/E ratio 2017 17,71
P/E ratio 2018 16,48
EV / Sales 2017 2,15x
EV / Sales 2018 2,00x
Capitalization 96 546 M
More Financials
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 118 €
Spread / Average Target 1,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Human Resources, Technology & Sustainability
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG18.68%108 081
JOHNSON & JOHNSON10.68%343 545
ROCHE HOLDING LTD.14.88%236 038
NOVARTIS AG6.68%212 104
PFIZER INC.-1.32%191 517
MERCK & CO., INC.10.48%177 895
More Results